share_log

华熙生物(688363.SH):公司是国内较早认识到中试环节重要性并率先建设合成生物中试转化平台的企业

Huaxi Biology (688363.SH): The company is a domestic enterprise that recognized the importance of the pilot phase earlier and took the lead in building a synthetic biology pilot transformation platform

Gelonghui Finance ·  May 24 03:33

Gelonghui, May 24 | Huaxi Biology (688363.SH) said on the investor interactive platform that as the earliest domestic enterprise to lay out synthetic biology, the company has built a full synthetic bio green manufacturing industry chain covering “R&D innovation, pilot testing, industrial transformation, and market transformation”, and has full chain capabilities from “gene editing, strain transformation, cell engineering creation, to pilot testing and industrial transformation, to market transformation”. At the same time, the company is also a domestic enterprise that recognized the importance of the pilot phase earlier and took the lead in building a synthetic biology pilot transformation platform. In 2023, the company used six major R&D platforms, including synthetic biology research and development platforms, to launch a total of 9 new bioactive ingredient products: 3 pharmaceutical/medical device-grade raw material products, 4 personal care ingredient products, and 2 food-grade raw material products. At the same time, microcrosslinked hyaluronic acid powder products HyacrosSTL200, cationic HA, enzymatic sialic acid, polyoligonucleotides, GABA fabric finishing agent, Cordyceps sinensis fermentation liquid, probiotic combination ferment, etc. have completed trial production, and rhododoside, carnosine, and human milk oligosaccharide have completed pilot testing.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment